MicroRNA‑449a is a potential predictor of colitis‑associated colorectal cancer progression

Feng,Yun; Dong,Yu‑Wei; Song,Yun‑Na; Xiao,Jun‑Hua; Guo,Xing‑Ya; Jiang,Wei‑Liang; Lu,Lun‑Gen

doi:10.3892/or.2018.6566

MicroRNA‑449a is a potential predictor of colitis‑associated colorectal cancer progression

Authors:
- Yun Feng
- Yu‑Wei Dong
- Yun‑Na Song
- Jun‑Hua Xiao
- Xing‑Ya Guo
- Wei‑Liang Jiang
- Lun‑Gen Lu
View Affiliations

Affiliations: Department of Gastroenterology, Shanghai General Hospital of Nanjing Medical University, Shanghai 200080, P.R. China, Department of Gastroenterology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, P.R. China, Department of Gastroenterology, Qihe People's Hospital, Dezhou, Shandong 251100, P.R. China, Department of Gastroenterology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, P.R. China, Department of Gastroenterology, Shanghai General Hospital of Nanjing Medical University, Shanghai 200080, P.R. China
Published online on: July 12, 2018 https://doi.org/10.3892/or.2018.6566
Pages: 1684-1694

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

An early diagnosis of colitis‑associated colorectal cancer (CAC) is important for its clinical management. However, it is currently difficult to distinguish the different stages of CAC development. MicroRNA dysregulation is common in human colorectal disorders, however little is known regarding whether miRNA affects tumor progression by regulating inflammation. In the present study, we identified a novel miRNA (miR‑449a), the expression of which was significantly reduced in CAC tissues than in paired adjacent non‑cancerous tissues (ANTs). Notably, the level of miR‑449a was in a markedly decreased pattern during the neoplastic transformation of ulcerative colitis (UC)‑to‑CAC, as demonstrated by both clinical investigations and the experimental mouse model induced by AOM/DSS treatment. In addition, we observed that decreased miR‑449a expression was associated with advanced T or N status, later clinical stage and poor histological differentiation of CAC. Mechanistic studies revealed that miR‑449a inhibited the growth and metastasis of human colon cancer cells by directly binding to the 3'‑UTR of Notch‑1 and thereby, suppressed the activation of the Notch signaling pathway. Therefore, these findings provide strong evidence for the translational potential of miR‑449a in the discrimination of patients with UC that is likely to progress into CAC, from those unlikely to progress, as well as in the prognosis and diagnosis of CAC.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
2	Abraham C and Cho JH: Inflammatory bowel disease. N Engl J Med. 361:2066–2078. 2009. View Article : Google Scholar : PubMed/NCBI
3	Kaplan GG and Ng SC: Globalisation of inflammatory bowel disease: Perspectives from the evolution of inflammatory bowel disease in the UK and China. Lancet Gastroenterol Hepatol. 1:307–316. 2016. View Article : Google Scholar : PubMed/NCBI
4	Fumery M, Dulai PS, Gupta S, Prokop LJ, Ramamoorthy S, Sandborn WJ and Singh S: Incidence, risk factors, and outcomes of colorectal cancer in patients with ulcerative colitis with low-grade dysplasia: A systematic review and meta-analysis. Clin Gastroenterol Hepatol. 15:665–674.e5. 2017. View Article : Google Scholar : PubMed/NCBI
5	Rogler G: Chronic ulcerative colitis and colorectal cancer. Cancer Lett. 345:235–241. 2014. View Article : Google Scholar : PubMed/NCBI
6	Eaden JA, Abrams KR and Mayberry JF: The risk of colorectal cancer in ulcerative colitis: A meta-analysis. Gut. 48:526–535. 2001. View Article : Google Scholar : PubMed/NCBI
7	Herrinton LJ, Liu L, Levin TR, Allison JE, Lewis JD and Velayos F: Incidence and mortality of colorectal adenocarcinoma in persons with inflammatory bowel disease from 1998 to 2010. Gastroenterology. 143:382–389. 2012. View Article : Google Scholar : PubMed/NCBI
8	Sebastian S, Hernández V, Myrelid P, Kariv R, Tsianos E, Toruner M, Marti-Gallostra M, Spinelli A, van der Meulen-de Jong AE, Yuksel ES, et al: Colorectal cancer in inflammatory bowel disease: Results of the 3rd ECCO pathogenesis scientific workshop (I). J Crohns Colitis. 8:5–18. 2014. View Article : Google Scholar : PubMed/NCBI
9	Yashiro M: Ulcerative colitis-associated colorectal cancer. World J Gastroenterol. 20:16389–16397. 2014. View Article : Google Scholar : PubMed/NCBI
10	Ording AG, Horváth-Puhó E, Erichsen R, Long MD, Baron JA, Lash TL and Sørensen HT: Five-year mortality in colorectal cancer patients with ulcerative colitis or Crohn's disease: A nationwide population-based cohort study. Inflamm Bowel Dis. 19:800–805. 2013. View Article : Google Scholar : PubMed/NCBI
11	Itzkowitz SH and Yio X: Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: The role of inflammation. Am J Physiol Gastrointest Liver Physiol. 287:G7–G17. 2004. View Article : Google Scholar : PubMed/NCBI
12	Luo C and Zhang H: The role of proinflammatory pathways in the pathogenesis of colitis-associated colorectal cancer. Mediators Inflamm. 2017:51260482017. View Article : Google Scholar : PubMed/NCBI
13	Kinugasa T and Akagi Y: Status of colitis-associated cancer in ulcerative colitis. World J Gastrointest Oncol. 8:351–357. 2016. View Article : Google Scholar : PubMed/NCBI
14	Mendell JT and Olson EN: MicroRNAs in stress signaling and human disease. Cell. 148:1172–1187. 2012. View Article : Google Scholar : PubMed/NCBI
15	Ambros V: MicroRNAs and developmental timing. Curr Opin Genet Dev. 21:511–517. 2011. View Article : Google Scholar : PubMed/NCBI
16	Saraggi D, Fassan M, Mescoli C, Scarpa M, Valeri N, Michielan A, D'Incá R and Rugge M: The molecular landscape of colitis-associated carcinogenesis. Dig Liver Dis. 49:326–330. 2017. View Article : Google Scholar : PubMed/NCBI
17	Romano M, De Francesco F, Zarantonello L, Ruffolo C, Ferraro GA, Zanus G, Giordano A, Bassi N and Cillo U: From inflammation to cancer in inflammatory bowel disease: Molecular perspectives. Anticancer Res. 36:1447–1460. 2016.PubMed/NCBI
18	Schlemper RJ, Riddell RH, Kato Y, Borchard F, Cooper HS, Dawsey SM, Dixon MF, Fenoglio-Preiser CM, Fléjou JF, Geboes K, et al: The Vienna classification of gastrointestinal epithelial neoplasia. Gut. 47:251–255. 2000. View Article : Google Scholar : PubMed/NCBI
19	Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L and Colombel JF: Ulcerative colitis. Lancet. 389:1756–1770. 2017. View Article : Google Scholar : PubMed/NCBI
20	Torres J, Mehandru S, Colombel JF and Peyrin-Biroulet L: Crohn's disease. Lancet. 389:1741–1755. 2017. View Article : Google Scholar : PubMed/NCBI
21	Bader JE, Enos RT, Velázquez KT, Carson MS, Nagarkatti M, Nagarkatti PS, Chatzistamou I, Davis JM, Carson JA, Robinson CM, et al: Macrophage depletion using clodronate liposomes decreases tumorigenesis and alters gut microbiota in the AOM/DSS mouse model of colon cancer. Am J Physiol Gastrointest Liver Physiol. 314:G22–G31. 2018. View Article : Google Scholar : PubMed/NCBI
22	Fang Z, Yin S, Sun R, Zhang S, Fu M, Wu Y, Zhang T, Khaliq J and Li Y: miR-140-5p suppresses the proliferation, migration and invasion of gastric cancer by regulating YES1. Mol Cancer. 16:1392017. View Article : Google Scholar : PubMed/NCBI
23	Shen J, Zhang S, Li Y, Zhang W, Chen J, Zhang M, Wang T, Jiang L, Zou X, et al: p14ARF inhibits the functions of adenovirus E1A oncoprotein. Biochem J. 434:275–285. 2011. View Article : Google Scholar : PubMed/NCBI
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
25	Vinson KE, George DC, Fender AW, Bertrand FE and Sigounas G: The Notch pathway in colorectal cancer. Int J Cancer. 138:1835–1842. 2016. View Article : Google Scholar : PubMed/NCBI
26	Li G, Zhou Z, Zhou H, Zhao L, Chen D, Chen H, Zou H, Qi Y, Jia W and Pang L: The expression profile and clinicopathological significance of Notch1 in patients with colorectal cancer: A meta-analysis. Future Oncol. 13:2103–2118. 2017. View Article : Google Scholar : PubMed/NCBI
27	Lamy M, Ferreira A, Dias JS, Braga S, Silva G and Barbas A: Notch-out for breast cancer therapies. N Biotechnol. 39:215–221. 2017. View Article : Google Scholar : PubMed/NCBI
28	Mercey O, Popa A, Cavard A, Paquet A, Chevalier B, Pons N, Magnone V, Zangari J, Brest P, Zaragosi LE, et al: Characterizing isomiR variants within the microRNA-34/449 family. FEBS Lett. 591:693–705. 2017. View Article : Google Scholar : PubMed/NCBI
29	Wang LG, Ni Y, Su BH, Mu XR, Shen HC and Du JJ: MicroRNA-34b functions as a tumor suppressor and acts as a nodal point in the feedback loop with Met. Int J Oncol. 42:957–962. 2013. View Article : Google Scholar : PubMed/NCBI
30	Jiang L and Hermeking H: miR-34a and miR-34b/c suppress intestinal tumorigenesis. Cancer Res. 77:2746–2758. 2017. View Article : Google Scholar : PubMed/NCBI
31	Wallace KL, Zheng LB, Kanazawa Y and Shih DQ: Immunopathology of inflammatory bowel disease. World J Gastroenterol. 20:6–21. 2014. View Article : Google Scholar : PubMed/NCBI
32	Peyrin-Biroulet L, Panés J, Sandborn WJ, Vermeire S, Danese S, Feagan BG, Colombel JF, Hanauer SB and Rycroft B: Defining disease severity in inflammatory bowel diseases: Current and future directions. Clin Gastroenterol Hepatol. 14:348–354.e7. 2016. View Article : Google Scholar : PubMed/NCBI
33	Hata K, Kishikawa J, Anzai H, Shinagawa T, Kazama S, Ishii H, Nozawa H, Kawai K, Kiyomatsu T, Tanaka J, et al: Surveillance colonoscopy for colitis-associated dysplasia and cancer in ulcerative colitis patients. Dig Endosc. 28:260–265. 2016. View Article : Google Scholar : PubMed/NCBI
34	Feuerstein JD and Cheifetz AS: Ulcerative colitis: Epidemiology, diagnosis, and management. Mayo Clinic Proc. 89:1553–1563. 2014. View Article : Google Scholar
35	Bressenot A, Cahn V, Danese S and Peyrin-Biroulet L: Microscopic features of colorectal neoplasia in inflammatory bowel diseases. World J Gastroenterol. 20:3164–3172. 2014. View Article : Google Scholar : PubMed/NCBI
36	Chen R, Lai LA, Brentnall TA and Pan S: Biomarkers for colitis-associated colorectal cancer. World J Gastroenterol. 22:7882–7891. 2016. View Article : Google Scholar : PubMed/NCBI
37	Lujambio A and Lowe SW: The microcosmos of cancer. Nature. 482:347–355. 2012. View Article : Google Scholar : PubMed/NCBI
38	de Santa Barbara P, van den Brink GR and Roberts DJ: Development and differentiation of the intestinal epithelium. Cell Mol Life Sci. 60:1322–1332. 2003. View Article : Google Scholar : PubMed/NCBI
39	Fazio C and Ricciardiello L: Inflammation and Notch signaling: A crosstalk with opposite effects on tumorigenesis. Cell Death Dis. 7:e25152016. View Article : Google Scholar : PubMed/NCBI
40	Takebe N, Nguyen D and Yang SX: Targeting notch signaling pathway in cancer: Clinical development advances and challenges. Pharmacol Ther. 141:140–149. 2014. View Article : Google Scholar : PubMed/NCBI
41	Chu D, Zhang Z, Zhou Y, Wang W, Li Y, Zhang H, Dong G, Zhao Q and Ji G: Notch1 and Notch2 have opposite prognostic effects on patients with colorectal cancer. Ann Oncol. 22:2440–2447. 2011. View Article : Google Scholar : PubMed/NCBI